Form 4: Calidi Biotherapeutics Director Acquires Stock Options

James A. Schoeneck, a director of Calidi Biotherapeutics, acquired non-qualified stock options for 20,217 shares of common stock.

Summary

• On October 15, 2024, a Form 4 filing was submitted to the SEC regarding James A. Schoeneck's transaction involving Calidi Biotherapeutics, Inc. [CLDI].
• Schoeneck, a director of Calidi Biotherapeutics, acquired non-qualified stock options to purchase 20,217 shares of common stock.
• The options were granted on September 20, 2024, with an exercise price of $1.09 per share, which was the closing price on the grant date.
• The options vest in monthly installments over one year, commencing on the grant date, and expire on September 20, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the options suggests a long-term commitment from the director.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates